A Phase 1 Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of GS-1811, an Afucosylated Anti-CCR8 Monoclonal Antibody, as Monotherapy and in Combination with an anti-PD-1 Monoclonal Antibody in Adults with Advanced Solid Tumors
NCT #
NCT05007782
Condition(s)
Breast Cancer, Cervical Cancer, Colorectal Cancer, Esophageal Cancer, Gastric/GEJ Cancer, Head and Neck Cancer, Lung Cancer (NSCLC), Skin Cancer/ Melanoma, Vaginal Cancer, Vulvar Cancer
Molecular Target(s)
CCR8
Drug Classification(s)
Monoclonal Antibody
Agents(s)
monoclonal antibody
Phase(s)
I
Mechanism of Action
GS-GS-1811 is a monoclonal antibody that is designed to bind to CCR8. It is thought to target Tumor-Infiltrating T Regulatory cells for depletion by enhancing an antibody-dependent cellular cytotoxicity mechanism
Purpose
- How much of the study agent when given alone or in combination with Zimberelimab can be given with an acceptable level of side effects
- About the safety, tolerability, and effectiveness of the study agent when given alone or in combination with Zimberelimab
- Whether the study agent in combination with Zimberelimab or Zimberelimab alone is more effective
- How much of the study agent is absorbed into your blood and how fast it is removed from your blood
- If research tests can be used in the future to predict who will benefit from GS1811
- How your body responds to taking GS-1811 alone or in combination with Zimberelimab
Location
MCD
Connect With Us
Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.